SCHEMBL21246544

SCHEMBL21246544

CCc1ccc(C(=O)NCc2cccnc2)cc1N

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
L3MBTL1 Q9Y468 3/20 0.63
NPSR1 Q6W5P4 2/20 0.63
USP2 O75604 1/20 0.63
LMNA P02545 3/20 0.62
HTT P42858 3/20 0.62
MAPT P10636 1/20 0.62
MAPK1 P28482 1/20 0.61
TSHR P16473 3/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 2/20 0.61
BLM P54132 1/20 0.61
GAA P10253 1/20 0.60
TRPV1 Q8NER1 1/20 0.60
CYP2C19 P33261 1/20 0.60
CA2 P00918 1/20 0.59
MMP13 P45452 1/20 0.57
POLB P06746 1/20 0.57
HPGD P15428 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29437175 0.88 ALDH1A1 (0.63) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL21222734 0.88 ALDH1A1 (0.63) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL29437181 0.85 LMNA (0.61) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL21246563 0.85 NPSR1 (0.62) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL10323920 0.85 LMNA (0.61) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL21246573 0.84 ALDH1A1 (0.80) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL14030202 0.83 L3MBTL1 (0.64) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL10076246 0.83 TRPV1 (0.74) ALDH1A1NPSR1LMNAHTTMAPT
SCHEMBL12426371 0.82 ALDH1A1 (0.80) ALDH1A1L3MBTL1NPSR1USP2LMNA
SCHEMBL1047604 0.81 CA2 (0.71) ALDH1A1L3MBTL1NPSR1USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2025-08-19 US disclosed
US-20230099912-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-03-30 US disclosed
EP-3747866-B1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INST MATERIA MEDICA CAMS (CN) 2023-03-01 EP disclosed
US-11518744-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-12-06 US disclosed
US-11518744-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-12-06 US disclosed
CN-110092743-B Benzamide compound, preparation method, application and pharmaceutical composition thereof 中国医学科学院药物研究所 2022-03-15 CN disclosed
US-20210047270-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2021-02-18 US disclosed
EP-3747866-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2020-12-09 EP disclosed
EP-3747866-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2020-12-09 EP disclosed
WO-2019149223-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF 中国医学科学院药物研究所 2019-08-08 WO disclosed
CN-110092743-A Benzamide compound and preparation method thereof, purposes and pharmaceutical composition 中国医学科学院药物研究所 2019-08-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof JAK2, STAT3, STAT5A ALDH1A1 635/4885L3MBTL1 4608/4885NPSR1 2203/4885
US-20230099912-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF JAK2, STAT3, STAT5A ALDH1A1 635/4885L3MBTL1 4608/4885NPSR1 2203/4885
US-20210047270-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF JAK2, STAT3, STAT5A ALDH1A1 635/4885L3MBTL1 4608/4885NPSR1 2203/4885
US-11518744-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof JAK2, STAT3, STAT5A ALDH1A1 635/4885L3MBTL1 4608/4885NPSR1 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.